Molecular therapy for Myocardial dysfunction: MiR-296 increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene, 27/October/2016, 6.17 am

Natural product Lifespan extension therapy: Isorhapontigenin, isolated from Aiphanes Aculeata, Norway/Sitka/white Spruce, among others, increases life span via up-regulation of its target gene BubR1, 26/October/2016, 3.18 pm
October 26, 2016
Natural product anti-inflammatory therapy for upper respiratory tract inflammatory diseases: Berberine increases the expression of negative regulator of inflammation MyD88(s), inhibits pro-inflammatory mediators in lungs, and alleviates the common respiratory pathogen nontypeable Haemophilus influenzae (NTHi)-exacerbated asthma & chronic obstructive pulmonary disease via up-regulation of its target gene, 27/October/2015, 6.33 am
October 27, 2016
Show all

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports here that: Molecular therapy for Myocardial dysfunction: MiR-296 increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene



Significance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.


Research Findings: 

MiR-296, by decreasing the expression of its target gene,  it may: (1) increase the expression of marker of autophagy LC3-II, 2) inhibit selective autophagy receptor p62/sequestosome 1 (SQSTM1) expression,  3) inhibit the expression of negative regulator of autophagy, mTOR, 4) promote autophagy, 5) increase CDK inhibitor p27 expression, 6) decrease left ventricular end-diastolic internal diameter and heart size, and (5) inhibit cardiomyocyte dysfunction. Together, this study suggests that pharmacological formulations encompassing MiR-296 activators” may function as myocardial protective agents and be used to improve cardiac function.


Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Molecular therapy for Myocardial dysfunction: MiR-296 increases CDK inhibitor p27 expression, inhibits mTOR pathway, promotes autophagy in myocardial cells and prevents myocardial dysfunction via down-regulation of its target gene, 27/October/2016, 6.17 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation


Amount: $200

Undisclosed information: How MiR-296 promotes autophagy in cardiomyocytes and prevents heart failure.

satisfaction-guaranted-if-not-refunded

Results guaranteed if not refunded

Comments are closed.